Company: American Public Education, Inc. (APEI)
Date of Analysis: August 24, 2025
Primary Sources Reviewed: Form 10-K filed March 5, 2025, for the fiscal year ended December 31, 2024.

**1) Products/Services with Long Runway**
**Question:** Does the company have products or services with sufficient market potential to make possible a sizable increase in sales for at least several years?
**Reasoning & Evidence:** APEI is positioned in two markets with durable, long-term demand drivers: nursing education and military/veteran education. The U.S. Bureau of Labor Statistics projects the need for approximately 194,500 new registered nurses annually through 2033, addressing a persistent national shortage. The company also serves a large veteran population, estimated at 6.4 million in the prime education-seeking age groups of 18-54 in 2024, who require ongoing upskilling for civilian careers. These factors provide a substantial and sustained market for APEI's core offerings.
**Answer:** Yes
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**2) Commitment to Ongoing Development**
**Question:** Does management have a determination to continue to develop products or processes that will further increase total sales potential once current lines mature?
**Reasoning & Evidence:** Management's strategy explicitly targets growth through ongoing development. A major strategic initiative is the planned combination of its APUS, Rasmussen, and Hondros units into a single university system, which is intended to "facilitate innovation across the Company." The company also states a focus on "expanding nursing opportunities through geographic campus expansion and the expansion of our programs and course offerings," including both organic and inorganic growth. This demonstrates a clear commitment to evolving its business structure and product lines for future growth.
**Answer:** Yes
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**3) R&D Effectiveness Relative to Size**
**Question:** How effective are the company’s R&D efforts in relation to its size?
**Reasoning & Evidence:** The company does not report Research & Development as a distinct expense, making it impossible to compare its spending to peers. Costs related to creating new courses are capitalized as "Program development," which amounted to $14.9 million as of December 31, 2024. However, the company provides no specific metrics—such as new program success rates, time-to-market, or return on investment for this spending—that would allow an assessment of its effectiveness.
**Answer:** No
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**4) Above-Average Sales Organization**
**Question:** Does the company have an above-average sales organization?
**Reasoning & Evidence:** The company's sales and marketing performance is inconsistent across its segments. For the year ended December 31, 2024, net course registrations at the APUS segment grew by a modest 2.9%, but total student enrollment at the Rasmussen University segment declined by 1.3%. The company also explicitly discloses in its Risk Factors that it has "experienced challenges attracting" non-military students, indicating that its marketing efforts are not uniformly successful. These mixed results do not support a conclusion of an above-average sales organization.
**Answer:** No
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**5) Worthwhile Profit Margins**
**Question:** Does the company have a worthwhile profit margin?
**Reasoning & Evidence:** For the fiscal year ended December 31, 2024, APEI's consolidated income from operations was $33.1 million on $624.6 million of revenue, yielding an operating margin of 5.3%. This profitability is driven entirely by the APUS segment, which had a 28% operating margin. The Rasmussen and Hondros segments both generated operating losses for the year. The consolidated margin is modest and reliant on a single segment to offset losses elsewhere, indicating the overall business does not currently possess a worthwhile profit margin.
**Answer:** No
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**6) Margin Improvement Actions**
**Question:** What is the company doing to maintain or improve profit margins?
**Reasoning & Evidence:** Management is actively pursuing several initiatives to improve profitability. The most significant is the planned combination of APUS, Rasmussen, and Hondros, a strategic move aimed at "eliminating redundancies" and operating with "greater efficiency." The company has also exercised pricing power, implementing tuition increases at its institutions during 2024. Furthermore, APEI executed reductions in force in 2023 to realign its cost structure and optimize functions.
**Answer:** Yes
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**7) Labor & Personnel Relations**
**Question:** Does the company have outstanding labor and personnel relations?
**Reasoning & Evidence:** The evidence regarding labor relations is mixed. Management states that "employee relations to be good," and none of its employees are covered by a collective bargaining agreement. Full-time employee turnover improved to 14% in 2024 from 19% in 2023. However, the company explicitly acknowledges a key challenge: "A nursing faculty shortage continues, in certain markets, adversely affecting our ability to recruit and retain qualified nursing faculty at RU and HCN." This significant, persistent retention problem in a core business area prevents a conclusion of "outstanding" relations.
**Answer:** No
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**8) Executive Relations**
**Question:** Does the company have outstanding executive relations?
**Reasoning & Evidence:** The executive team demonstrates stability. The CEO, Angela K. Selden, has been in her role since September 2019. Other key leaders, such as the General Counsel, also have long tenures. While the company announced in 2024 that it was conducting an "orderly search" to replace its long-serving CFO, Richard Sunderland, this appears to be a planned transition rather than a sign of instability or conflict.
**Answer:** Yes
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**9) Depth of Management**
**Question:** Does the company have depth to its management?
**Reasoning & Evidence:** APEI's leadership structure shows significant depth. The 2024 10-K identifies eight senior executives, including not only corporate officers (CEO, CFO, CIO, GC, CHRO, CMO) but also dedicated presidents or CEOs for each of its primary educational institutions: APUS, Rasmussen University, and Hondros College of Nursing. This structure demonstrates a deep bench of operational leadership below the corporate level, with clear accountability for each major revenue-generating segment.
**Answer:** Yes
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**10) Cost Analysis & Accounting Controls**
**Question:** How good are the company’s cost analysis and accounting controls?
**Reasoning & Evidence:** The company's accounting controls appear robust. In its report for the year ended December 31, 2024, management concluded that its disclosure controls and procedures were effective. The company’s independent registered public accounting firm provided an unqualified opinion on the financial statements and the effectiveness of internal control over financial reporting as of December 31, 2024. The company also provides detailed segment-level financial reporting, indicating strong cost analysis capabilities.
**Answer:** Yes
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**11) Industry-Specific Competitive Clues**
**Question:** Are there other aspects of the business—peculiar to the industry—that give important clues about how outstanding the company may be versus competition?
**Reasoning & Evidence:** In for-profit education, regulatory compliance and student outcomes are critical competitive differentiators. APEI presents a mixed picture. APUS holds a powerful market position as the leading educator for U.S. active-duty military and veterans, a significant competitive advantage. However, the company's nursing schools have persistent problems with student outcomes, specifically poor pass rates on the NCLEX licensure exam, which has led to multiple campuses being placed on probation by state regulators. This significant regulatory and reputational issue at Rasmussen is a major competitive disadvantage that overshadows the strength at APUS.
**Answer:** No
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**12) Long-Range vs Short-Range Profit Outlook**
**Question:** Does the company have a long-range outlook in regard to profits (willing to trade near-term results for durable growth)?
**Reasoning & Evidence:** Management is making significant investments for long-term benefit at the expense of short-term results. The company is undertaking a complex consolidation of its three largest subsidiaries, incurring millions in professional fees ($2.2 million in 2024, with more expected in 2025) with the goal of creating a stronger, more efficient long-term structure. This action, combined with a stated focus on "sustainable growth," demonstrates a willingness to prioritize long-range strategic positioning over near-term profit maximization.
**Answer:** Yes
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**13) Equity Financing Dilution Risk**
**Question:** Is the company's financial position strong enough to fund foreseeable growth without resorting to equity financing that would meaningfully dilute existing shareholders?
**Reasoning & Evidence:** The company's financial position suggests potential reliance on external funding. While it generated $48.9 million in operating cash flow in 2024 and held $158.9 million in cash, it also had $93.4 million in long-term debt as of year-end. Critically, in December 2022, the company issued $40 million of Series A Senior Preferred Stock—a form of financing senior to common stock—to repay debt. This recent use of quasi-equity financing for balance sheet management indicates that purely internal funds may not be sufficient for all strategic capital needs, creating a risk of future financing that could dilute common shareholders.
**Answer:** No
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**14) Candor with Investors**
**Question:** Does management talk freely to investors when things are going well **and** when troubles occur (i.e., no “clam up”)?
**Reasoning & Evidence:** Management demonstrates a high degree of candor in its public filings. The 2024 10-K provides extensive, direct discussion of its most severe business challenges. It details the specific campuses with low NCLEX pass rates and their probationary status with state regulators. It also explains the complexities and risks associated with its compliance with the Department of Education's 90/10 Rule, which is a critical vulnerability for the APUS segment. This level of transparent detail on major problems suggests management does not "clam up" during difficult times.
**Answer:** Yes
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

**15) Unquestionable Integrity**
**Question:** Does the company have a management of unquestionable integrity?
**Reasoning & Evidence:** Based on public filings, there are no red flags suggesting a lack of integrity. The 2024 10-K states there are "no material legal proceedings pending." A review of the document reveals no related-party transactions involving executives, history of accounting restatements, or regulatory actions alleging fraud or misconduct by management. While the company faces significant regulatory compliance challenges, these appear to be operational issues rather than matters of questionable integrity.
**Answer:** Yes
**Citations:** [https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm](https://www.sec.gov/Archives/edgar/data/1201792/000120179225000004/apei-20241231.htm) (filed March 5, 2025)

---
**Synthesis**

American Public Education, Inc. scores positively on its long-term strategy, management depth, and transparency, but is held back by poor profitability and significant operational challenges in its nursing segment. The company's strongest positive is its clear focus on markets with durable demand (nursing and military) and its willingness to undertake a major corporate restructuring to improve long-term efficiency. However, its consolidated profit margins are weak, and the ongoing struggles with low nursing licensure exam pass rates at Rasmussen create significant regulatory and reputational risk. The two variables most likely to change the score in the next 12-24 months are the execution of the planned institutional combination and the NCLEX pass rates. Successful integration could unlock cost savings and improve margins, potentially flipping the "Worthwhile Profit Margins" point to 'Yes'. A sustained, measurable improvement in NCLEX pass rates across Rasmussen campuses would be the key evidence needed to change the "Industry-Specific Competitive Clues" and "Above-Average Sales Organization" points from 'No' to 'Yes'.

**fisher score is 9 / 15**